Thanks for visiting Scientific Computing World.

You're trying to access an editorial feature that is only available to logged in, registered users of Scientific Computing World. Registering is completely free, so why not sign up with us?

By registering, as well as being able to browse all content on the site without further interruption, you'll also have the option to receive our magazine (multiple times a year) and our email newsletters.

Elan Pharmaceuticals choses RISe for informatics

Share this on social media:

Infosys Technologies has announced that it will design and implement the Research Informatics System (RISe) at Elan Pharmaceuticals, a leading biotechnology company, to accelerate research using a path-breaking co-creation engagement model that leverages Infosys’ existing intellectual property in this field.

'We are confident that partnering and collaborating with Infosys will create a comprehensive informatics platform for our discovery research needs,' said Ajay Shah, director or research informatics at Elan Pharmaceuticals. 'We selected Infosys after a competitive proof-of-concept phase during which they fully established their credentials and investments in this changing field of discovery research, and demonstrated flexibility and maturity in terms of rapid application development using Agile and Scrum methodologies. With Infosys’ solution and engagement model, Elan will be able to lower costs for scientific operation and facilitate innovation.'

As Elan’s informatics system, RISe will leverage Infosys’ scientific innovation solution for knowledge collaboration. Novel ways to unlock disparate data spread across in-house research labs and other commercial or public sources will be presented to scientists in context of their research needs. This will result in, among other things, a customised registry and inventory, along with a workflow management system for biological entities.

Elan and its research partners could realise significant gains in research productivity by focused and efficient selection of candidate drugs or molecules with the new RISe. Linking silos of heterogeneous data will not only contribute to a more effective selection process of candidate molecules, but could also reduce time to validate them clinically. Furthermore, the new system will reduce time spent on registering and experimenting with bio-entities, increase collaboration, and reduce chances of downstream failure.

Future versions of the software may enable integration of RISe with electronic lab notebook and analytical dashboards which will enable more efficient research knowledge management.